A recent study published in the Clinical Research in Cardiology journal linked impaired high-density lipoprotein (HDL) ...

The following is a summary of “Reduced antioxidant high-density lipoprotein function in heart failure with preserved ejection ...

Research led by Professor Hai-Ling Margaret Cheng (BME) opens the door to earlier treatment and better outcomes ...

where this difference may be related to fewer coronary heart deaths in HFPEF. Key mortality risk factors, including age, gender, body mass index, burden of co-morbidities, and coronary artery ...

Obesity significantly impacts cardiovascular health, increasing risks such as left ventricular hypertrophy, atherosclerosis, ...

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal ...

The market opportunity within HFpEF is the critical factor driving TX45's NPV ... There's always a risk that TX45 might not meet its primary endpoints. Unexpected side effects or trial delays ...

The current study is an extension of the PREVEND community-based European cohort, which previously investigated risk factors for HFrEF and HFpEF development. Investigators looked at lifetime risk of ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease ... failure with preserved ejection fraction (HFpEF) – a particularly hard-to-treat form ...

“[This was] after accounting for differences in age, race and ethnicity, and clinical factors known ... older men.” The risk of heart failure, including HFpEF, became “significantly lower ...